Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast, Q1'26

By Inderes5/12/2026, 12:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:00

Go ahead.

Fredrik Tiberg
00:01 - 02:30

Thank you so much. Good day, everyone, and welcome to our first earnings call in 2026. Please note first our forward-looking statements. Here is the agenda for today. I'll start with the highlights. Anders will cover the financials. Richard will cover the commercial update. And I'll return with a pipeline update and key takeaways before moving to Q&A. Starting with a few words on the quarter. As we stated in the report released earlier today, Q1 was on track with our full year guidance. Revenues recovered following the UK distribution model change, and we made continued financial progress across our commercial programs and development pipeline. Total revenues were 533 million SEK, a 15% increase versus previous quarter, but a 5% decline year on year, driven by FX and channel phasing in 2025. We maintained strong profitability with a 32% operating margin and ended the quarter with 3.9 billion SEK in cash. Importantly, we look forward to a robust growth trajectory for the rest of 2026. Commercially reported product sales were down 12% year on year, or 6% at constant exchange rate. However, underlying in-market growth was significant. Buvidal grew 17% and Oczyesa delivered its first full commercial quarter with 4 million SEK in net sales in Germany alone. Brixadi royalties increased 44%, or 59% at constant exchange rate. And on the pipeline side. The pipeline will be particularly eventful in the coming quarters. The FDA accepted the Oclaiz NDA in the US with an anticipated decision date of 10th of June this year, and SORENTO continues to progress towards the primary readout in GEP-NET. I'll come back to both of these programs later on in the call. With that said, Anders, over to you for financials.

Anders Vadsholt
02:31 - 05:15

Thank you Fredrik. The first financial quarter results met our expectations. Moving to the next slide, you can see the main components of the profit and loss. Camurus reported quarterly revenue of 533 million, down from 558 million, a 5% year-on-year decrease. However, at constant exchange rates, revenues grew by 3%. The overall decline is primarily due to the unfavorable currency effect and channel phasing on a sequential basis. Revenue increased by 15% from Q4, driven by a one-time impact of $93 million resulting from the change in the UK distribution model in the previous quarter; total opex for the quarter amounted to 328 million SEK, a 13% increase year-on-year, primarily driven by the continued investment in commercialisation and R&D. Marketing and distribution costs increased to 130 million, fuelled by the expansion of Buvidal and Oczyesa, as well as the company's entry to the US market. Administrative expenses reached 47 million. R&D spending was 138 million, an increase of 7 million year over year. For clarity, the anticipated significant increase in R&D and US launch spend will primarily occur in the second half of this year. The operating result for the quarter was 168 million, down 30%, or 15% at constant exchange rates, compared to the same period last year. The operating margin was 32% and earnings per share before dilution were 2.42 SEK. Moving to the next slide showing the cash flow. The quarter's cash flow showed a 150 million SEK increase in the cash position compared to the end of 2025, primarily driven by a solid operating cash flow of 162 million. The change in working capital had a modest negative impact of 9 million, primarily due to the reduced accounts payable and increased trade receivables. Cash flow from investing activities was -39 million, primarily due to the establishment of a second manufacturer for Oclaiz in the US. Financing activities added 21 million, mainly from the exercise of employee stock options. This resulted in a very strong cash position of 3.876 billion at the end of Q1, a 35% increase compared to the same period last year. This solid financial position gives us the flexibility to continue investing in our pipeline, expand our global commercial operation and see strategic opportunities as they arise, all while creating sustainable value for our shareholders. With that, I'll hand over to Richard.

Richard Jameson
05:16 - 09:41

Thank you, Anders. So, starting with Buvidal, the quarter was in line with our guidance assumptions. Reported sales of 422 million SEK were down 13% year on year, or 7% on a constant exchange rate basis, which reflects the UK channel phasing we've discussed. The more meaningful metric is in-market sales, which grew 17% year on year. So underlying demand is strong. Nordics, Germany, France and Spain saw robust growth and Portugal saw rapid initial uptake following the release of funding to the treating clinics. Overall healthcare professional and patient response in Portugal has been very positive, as we've seen in other markets. In Australia, we saw the usual seasonal softness from the summer period. Sales there typically build in Q4 ahead of the vacations before normalizing in Q1. The UK remains a focus area. Funding restraints from the prior year carried into Q1, but importantly, a new three-year budget was announced for the NHS financial year starting the 1st of April. We expect this to lead to meaningfully improved patient access going forward, and during the quarter, some notable policy support for Buvidal was published in both England and Wales, with calls for more access and funding for long-acting buprenorphine. In Germany, the Federal Audit Office, which carries significant weight politically, has recommended shifting physician remuneration for opioid dependence treatment away from dispensing payments towards consultation and coordination of services, and has called on the Ministry of Health to update the reimbursement framework accordingly. If and when implemented. When implemented, this structural change is expected to remove a key barrier to patient access to innovative treatments for opioid dependence. And at the end of the quarter, approximately 73,000 patients were estimated to be in treatment with Buvidal, and we continued working towards our 2027 ambition of 100,000 patients. Now, turning to the US, Brixadi royalties in Q1 were 106 million SEK, up 44% year on year and 59% at constant exchange rates. The quarter did see some seasonal softness from prior annual prior authorization renewals and payer mix dynamics, both of which we expect to normalize as the year progresses and the underlying trajectory remains very strong. Brixadi's equivalent unit share reached approximately 32% of the US long-acting injectable buprenorphine segment, according to external audit data, which is up from 26% a year ago. And the segment itself is growing more than 30% year on year. So we're gaining share in an expanding market. Braeburn continues to invest materially in the franchise, including expanded patient-facing commercial activities, and we remain confident in a strong trajectory through 2026. Now, moving across to the launch of Oczyesa in Germany, where we had a good first full quarter, sales reached 4.2 million SEK, with approximately 50 patients in treatment, representing about 2.5% share after just one quarter. The product profile is resonating with both patients and physicians, and whilst we anticipate the rate of uptake to normalize going forward due to the cadence of patients visiting clinics, we continue to expect penetration towards a double-digit share in Germany by year-end. Beyond Germany, launch preparations are advancing in the UK. We've secured listing on the NHS National Framework Agreement and have submitted 13 formal applications, and pricing approvals are in place in Norway and Sweden, and sales and medical teams are in place across our wave one markets. The opportunity in initial launch markets is an estimated 3 to 5000 patients on current standard of care. Somatostatin analogues and market research indicates a 30 to 60% willingness to switch. Now, turning to Oclaiz in the US, with the FDA PDUFA action date less than a month from today, our US commercial team organization is launch ready. The core team has spent the last year executing a comprehensive pre-launch plan across every workstream. With these foundations in place, we are well positioned for an anticipated US launch of Oclaiz in Q3 2026. With this, I'll hand back to Fredrik for the R&D update.

Fredrik Tiberg
09:43 - 14:26

Thank you. Moving over to a brief pipeline update. Starting with CAM2029, where we have three programs in parallel in Acromegaly, as Richard said, the date is set and we are ready to launch. And if, of course, we receive approval, we have a strong presence at the ongoing European Congress of Endocrinology in Prague, and we had a rapid fire oral presentation, several posters, and a symposium on new acromegaly treatments that attracted around 500 participants. The meeting is finishing this week. So it's been a very good showcase for our ACROINNOVA data that continues to build. And we look forward to an equally productive meeting at Endo in Chicago later this month. SORENTO is progressing according to plan. Event accrual is tracking towards the target of 194 progression-free survival events expected in the second half, and this will be followed by the readout of primary Phase 3 data. And as you know, with 332 patients across 12 countries, this is the largest randomized, sustained-release somatostatin analogue study in this indication to date. And a positive superiority outcome would be a major milestone for Camurus. And of course, also for patients in polycystic liver disease. We completed an end of phase two meeting with the FDA, and the first patients have now finished the two and a half year POSITANO extension study. The next steps will be informed by the FDA guidance and the extension data that is successfully coming through. And we will also in this area present new POSITANO results at EASL in Barcelona later this month with an oral presentation at the opening day. Moving over to the next program of interest, of course. CAM2056, we have continued to work on the preparations for the Phase 2b study, which is advancing and is set to initiate in the second half of this year following a Type B interaction with the FDA earlier in the quarter. In parallel, we are developing the final product format, including the Autoinjector pen for Phase 3 and commercialization. Our partnership programs have also advanced during the quarter, with Eli Lilly R&D activities on the long-acting incretins using our FluidCrystal technology progressing to plan, and with Gubra, we are jointly developing a long-acting PTH analog for Parathyroidism, where the candidate selection is planned for mid this year. And in addition, we have other new exciting programs advancing through early developments. So let me now turn to our priorities going forward. As you heard, the quarter is on track with full year guidance reaffirmed, as underlying commercial momentum is strong, with Buvidal in-market growth of 17%. Brixadi is up 59% at a constant exchange rate over the year, and Oczyesa had a good first quarter in Germany. From here, we expect performance to build through the year, supported by improved market access. The UK funding framework now in effect, continued Brixadi momentum and the continued European rollout of Oczyesa. Looking ahead, several potentially significant milestones are, of course, in front of us, including the Oclaiz FDA Action Date. The SORENTO completion and primary results, and together also with the start of the CAM2056 Phase 2b study. And of course, also our partnerships. So, all in all, we are confident in delivering on our 2026 objectives. And with that, I'll just let the floor open for questions. Please take over.

Operator
14:27 - 14:37

Thanks, Fredrik. The first question is from Gonzalo from Danske Bank. Please go ahead. Gonzalo. Your line is open. Gonzalo.

Gonzalo Artiach Castañon
14:38 - 15:26

Hello, everyone, and thank you for taking my questions. First, I think that it would be great if you could provide some color on the UK situation. And your report mentions that funding has now been announced, but when is this funding? In detail? Could you give us some color here on what is expected to arrive in clinics? Is it already in place since April 1st? Have you started seeing some kind of momentum or positive signals in the UK here? And I was wondering if you could also give us some color on your guidance range. And I don't know if you could provide some granularity on the top-line range that you provide. How much is the UK? How much of the UK's funding for clinics and its timing is baked into this range? Thank you so much.

Fredrik Tiberg
15:27 - 15:29

Thank you. Richard, do you want to start?

Richard Jameson
15:29 - 16:29

Yeah, sure. So, on the UK, obviously the multi-year funding framework that's been announced is a meaningful step forward. And it provides, I think, the commissioners of treatment a certainty over three years and removes one of those key barriers that was preventing prescribing, because some of the clinics didn't know whether they'd have continued funding. They now have that. We expect the effect to build gradually. It takes time for these budget allocations coming through, but we expect to see it during Q2 and then in the second half of the year. But the meaningful impact will be in the second half of the year. The grant itself is quite substantial. It's a total public health grant of approximately 13.4. I think it is billion pounds. Obviously, that's not just for substance misuse and other public health grants, but substance use is part of that program and that's a meaningful increase. And more than they've had before. So really, the summary is it's three years, which is important. And it's an increase that hasn't happened before. So we're positive that's going to make an impact.

Fredrik Tiberg
16:29 - 16:48

And maybe we should add that we're also working on other complementary activities. So this is a very important foundation, but we're also looking at other options going forward when it comes to the guidance range. Anders, do you want to take that question?

Anders Vadsholt
16:48 - 17:03

Maybe it's being too specific going into the UK numbers, but I can confirm that the Q1 result is in line with our internal projections. Also on the country level overall. But I can't go into specifics for the UK.

Gonzalo Artiach Castañon
17:05 - 17:32

Okay. No, that's clear. Thank you very much. One question. Regarding Buvidal, in your report, you say that you're expecting completion of events needed in the SORENTO study to close in H2. And from what you know now, are you expecting this more towards Q4? Push potentially read out to Q1 next year, or are you expecting a readout this year as well? Sorry.

Fredrik Tiberg
17:32 - 17:38

We haven't changed our – I assume you didn't mean Buvidal, but rather CAM2029.

Gonzalo Artiach Castañon
17:39 - 17:40

Yeah. Sorry. Sorry.

Fredrik Tiberg
17:40 - 17:54

Yes. Yeah. Yeah. So, we maintain our expectations to have the readout in the second half, or actually, to have the events occurring in the second half, I should say. And the readout shortly.

Gonzalo Artiach Castañon
17:55 - 17:56

Yeah.

Fredrik Tiberg
17:56 - 18:30

And the events come in. There are two pathways for that. So, we are expecting a large update at the end of May. So I will provide further clarity on the more detailed timeline once we have that. But as you know, event accrual is progressing in line with our expectation. But, you know, you need to have the last event to be able to close the trial. So, there is always going to be some uncertainty in these numbers coming in.

Gonzalo Artiach Castañon
18:32 - 18:34

Great. Thank you very much.

Fredrik Tiberg
18:34 - 18:34

Yeah.

Operator
18:36 - 18:39

The next question is from Romy O’Connor. From Kempen. Please go ahead.

Romy O’Connor
18:42 - 19:29

Hi team. Thank you for the presentation today. I have two quick questions. The first one, what do you expect the growth to look like for patients on Buvidal treatment, considering your target of 100,000 patients by year end? So if I'm looking at an additional 3000 patients on average quarter over quarter, how do you expect to reach your targets? And the second question, you also mentioned that collaborations with Lilly and Gubra have progressed with development candidate selection for Gubra plans. This year, are you able to provide some additional color on this or are there any insights on clinical development timelines? Thank you.

Fredrik Tiberg
19:33 - 19:35

Do you want to start out, Richard.

Richard Jameson
19:35 - 20:13

Yes, I can start with the path to 100,000. We set our ambition there for the end of 2027, and as you say, it needs a 3,000 net patient gain. Obviously, going forward, this will require continued progress in the market access programmes that we have ongoing. Obviously, the UK was a good step in the right direction, and we see that hopefully solving that problem. We've also got expanding geographies as well. Some new markets are picking up. Well, and we're going to be launching a couple of new markets relatively soon as well. So I think overall, we can still achieve that with the tracking that we're doing at the moment.

Fredrik Tiberg
20:16 - 20:22

Yeah. And Romy, could you please repeat the second question? So I have it.

Romy O’Connor
20:24 - 20:31

Yeah, it was just any additional insights on clinical development timelines with Lilly and Gubra?

Fredrik Tiberg
20:32 - 21:02

Unfortunately, we cannot provide any updates on the Lilly collaboration at this point. However, with Gubra, we are making good advances also in the preclinical side. And it's difficult to give direct estimates about when we can start clinical phase studies, but we are working effectively together with them. And I think, potentially next year.

Romy O’Connor
21:04 - 21:05

Great. Thank you.

Fredrik Tiberg
21:05 - 21:11

That's how far I can go, I think. Thank you. Romy.

Operator
21:12 - 21:16

Next question is from Christopher Uhde from SEB. Please go ahead. Christopher.

Christopher Uhde
21:18 - 22:26

Hi there. Christopher Uhde from SEB, thank you very much for taking my questions. I guess I'd start off on perhaps the U.S. side of things. Indivior made some interesting comments on its call, noting success with their rapid initiation, claiming they are the only ones who have that. And also the accelerated first dose. They talked a lot about their DTC and then, quote unquote enhanced service agreements with key specialty pharmacies and expecting to double volume growth basically year over year. What are your reflections on the relative importance of these various initiatives in limiting Brixadi uptake after what was initially an extremely fast launch? That has since moderated somewhat. Obviously, you're still getting, you know, taking share, as you've pointed out. But to what extent is Braeburn pursuing any of these kinds of efforts itself as well? That's my first question, please.

Fredrik Tiberg
22:27 - 24:14

Yeah. First of all, I think it's important to say that we are. We are looking. Braeburn's primary expansion potential is, of course, in the 90% of patients that are currently treated with sublingual therapy. But nonetheless, that's still a very important question that you have here. And in terms of the rapid initiation, we have, of course, had that from the beginning in terms of our weekly to monthly switch and the possibility of starting Brixadi directly, along with many other features that are still making Brixadi a strong offering. Into a very differentiated treatment, I think, for what I've seen from the Indivior regimen. Of course, they are giving two monthly doses within the first week, which is, of course, going to be positive, at least from a number of units perspective used at the start of treatment. So, that will definitely grow at least the initial part of the treatment. And I think it's useful for patients to have access to a new initiation regimen. We're seeing continued good uptake. So we, at least, feel quite comfortable with the situation we have and the differentiation that Brixadi has. Thank you. Anything else?

Christopher Uhde
24:15 - 25:03

Yeah. If you wouldn't mind, I was wondering about an article in the San Francisco Chronicle recently discussing Brixadi and Sublocade and the importance of initiating at the correct dose. And, and talking about patients who refused a second dose after experiencing withdrawal, I guess triggered by a too high dose of Brixadi. Would you please talk a little bit about the level of adherence? You see how it compares to the competition, to the best of what you're able to see? And can you quantify? Can you help us quantify how your broad range of doses contributes to this, and particularly in view of the fact that your competitors' low doses at the high end of what you offer?

Fredrik Tiberg
25:05 - 26:07

I think this is a very intricate discussion, and I'm happy to take it, but I think it's a little bit too complicated for this setting. It is true that very high initiation concentrations do have an impact in terms of the side effects that can be seen with buprenorphine, if that's what you're referring to. We have had this discussion in the European market. We see, for instance, now when patients are switched over to Brixadi or Buvidal in Europe, we see no changes whatsoever. And we see very high efficacy and very high retention. So I cannot speak to a specific report from one physician in San Francisco. It's difficult for me, but please share the information and I can follow up on that separately.

Christopher Uhde
26:08 - 26:52

I appreciate that. Thanks. If I could throw in one last question, just on Buvidal, so obviously the UK is apparently resolved. But how will the new framework really work? Structurally, does it potentially cap your growth in the UK over time, or is there a cap? And if there is a cap, is it so high that it doesn't matter in practical terms? Given the obviously slow start in the year from the UK, do you expect a full or partial recovery in revenue? Let's say perhaps from the perspective of consensus expectations.

Richard Jameson
26:54 - 27:49

Yes. Right now we're in the market, we're growing 17%. And you know, the reported sales are impacted by the change in distribution models that we've had in the UK. So, underlying that, the new funding, we do anticipate improving access to patients. Typically, numbers discussed in the UK suggest that somewhere between 20-25% of patients should have access to long-acting buprenorphine, at least in the first wave. And that's what they'll be heading to. The new money helps provide certainty around the three-year funding arrangement that increases over three years. It also supports that as well. And I think it's given confidence both to commissioners to commission now, because they know it can be a longer-term process, and also for providers of treatment to start initiating patients without the fear that the money might not be available next year. So it's given that certainty to the market.

Christopher Uhde
27:51 - 28:03

Okay. To clarify, should we see this as a phasing of what we were already expecting? Growing over 20% in Europe, or should we see it as perhaps moderating that slightly?

Richard Jameson
28:03 - 28:13

No, it's expected to grow. It takes time for that funding to come through to the clinics, of course, due to the bureaucracy involved. But we expect to see some signals in Q2 and then particularly in the second half.

Christopher Uhde
28:15 - 28:16

Thanks very much.

Fredrik Tiberg
28:17 - 28:18

Thank you.

Operator
28:19 - 28:24

Next question from Shan Hama. From Jefferies. Please go ahead.

Fredrik Tiberg
28:25 - 28:26

Hi, Shan.

Shan Hama
28:27 - 28:55

Hi. Thank you so much for taking my questions. I've got three. Please, if I may. And I'll take them one at a time. So firstly, if you were to sort of order the varying headwinds in terms of the level of impact from greatest to least for Buvidal, how would you order Australia seasonality, UK distribution model change FX? Um, yeah. How would you order those three in terms of level of impact?

Fredrik Tiberg
28:56 - 29:05

Yeah. I think we should limit that question to the headwinds in the quarter because I think we have quite a good outlook. But, Richard, maybe you take that.

Richard Jameson
29:06 - 29:38

Yeah. I'm not 100 percent sure what the question is really. We in Australia will pick up. The underlying growth is still there. So that's just seasonality that we know. So we see that it will be improved in Q2. The underlying growth in the UK will be reflected in Q2, rather than being impacted by the change in distribution model that we saw in Q1; and, as I previously mentioned, approximately half of the revenue change was attributable to FX effects and the other half to the distribution model change.

Shan Hama
29:41 - 30:08

Okay. That's clear. Thank you. And then my second question, please. I know you mentioned Braeburn is doing some work on the commercial and the sales front in terms of promoting Brixadi. We know that Indivior has a DTC program for. Sublocade. Is there anything similar for Brixadi or can you be a bit more specific on the specific things that Braeburn is doing to promote Brixadi?

Fredrik Tiberg
30:09 - 30:50

Well, as we are saying in this report, Braeburn is increasingly investing in direct-to-patient activities. I can't specify them. They are going various different routes. Of course, via everything from social media to direct interactions. And that is an initiative that has been ongoing for some time and accelerated during the first part of this year. So, and as I understand it, it's an investment that is having some good traction.

Shan Hama
30:52 - 31:05

Got it. That's clear. And then just one last one from me, please. When can we expect the full data for CAM2056 and in which format? So would it be a publication, a conference or perhaps both.

Fredrik Tiberg
31:05 - 31:08

Both. Yes, I would say second half.

Shan Hama
31:11 - 31:13

Got it. Thanks so much.

Operator
31:15 - 31:19

Next question from Richard Ramanius. From Redeye. Please go ahead. Richard.

Richard Ramanius
31:22 - 31:42

Hello. Good afternoon. I just have one question. Do you assume significant revenue contribution from Oclaiz and Oczyesa in your 2026 revenue guidance? Or if I phrase it like this, do you need revenue from Oclaiz and Oczyesa to reach your 2026 revenue guidance?

Fredrik Tiberg
31:42 - 31:47

I think we have been pretty modest. On that note, maybe, Anders, if you want to add.

Anders Vadsholt
31:47 - 31:58

Yes. So that can definitely be covered within the spread we have in the outlook. So it's not like it's so heavy as you're signaling in our assumptions.

Fredrik Tiberg
32:00 - 32:01

Is that clear enough?

Richard Ramanius
32:01 - 32:04

Okay. Thanks. Yeah. Thanks.

Fredrik Tiberg
32:04 - 32:05

Thank you.

Operator
32:06 - 32:11

Next one is from Georg Tigalonov-Bjerke. From ABG Sundal Collier. Please go ahead. George.

Georg Tigalonov-Bjerke
32:15 - 32:45

Hi, this is George from ABG. I have a two-part question on CAM2029 in GEP-NET, if I may please. So first, according to current tracking of a number of events, is the readout more likely to be announced towards the beginning or end of H2? And secondly, given a successful readout, I wonder if you can remind us of the timeline from this to market launch in the US and Europe, respectively. Thank you.

Fredrik Tiberg
32:47 - 34:39

Thank you. So in terms of the readout, as I said, we have a big data pool coming in later on this month. And I think it's difficult to give you more precise detail about when the events will occur. I would say very early in the second half is perhaps less likely. So if that's giving you some direction, that's probably as far as we can comment right now. And on the other topic, can you repeat that? Oh yes. You asked about the continued program. Obviously, a positive superiority outcome would position us extremely well in terms of demonstrating the performance of CAM2029 in GEP-NET, and the regulatory path from there on would be an NDA application to the FDA, submitted as quickly as possible post the data. And I think we have a very tight process there in place, and we believe that it's possible to have the approval, based on our assumption, within the fourth quarter of 2027. That's the expectation based on our current understanding and regulatory review in Europe. It will probably take slightly longer because of the assessment timelines. It would be an initial launch and approval plan for the US.

Georg Tigalonov-Bjerke
34:43 - 34:44

Great. I will say thank you very much.

Unknown 1
34:46 - 34:46

Thank you.

Operator
34:48 - 34:52

Next one is Matthias Haggblom from Handelsbanken. Please go ahead. Matthias.

Matthias Haggblom
34:54 - 35:13

Thank you so much. A couple of questions, please. First, on the option for Lilly to include Amylin as part of the June 2025 agreement. If Lilly decides not to pick up the option when it expires this summer, would you anticipate other interests for using FluidCrystal applied to Amylin from external parties?

Fredrik Tiberg
35:15 - 36:02

I think this is at this moment quite speculative. So I wouldn't really. But obviously, we will try to exploit our technology to its broadest application in indications which we consider suitable. So when it comes to the specific case of Amylin, let's wait and see how things evolve. We will be announcing any developments. I'm not sure where the timeline has been provided, but that's a question I cannot confirm. But otherwise, I would say that we'll update on that if it would become relevant.

Matthias Haggblom
36:04 - 36:15

Could I rephrase? Maybe so. So when you signed the deal in June 2025, was there competitive interest except Eli Lilly to include incretins as part of FluidCrystal?

Fredrik Tiberg
36:16 - 36:29

We do have a significant interest in different applications and modes of action, of course, for the FluidCrystal technology. And we did so also before signing the agreement. Yes.

Matthias Haggblom
36:31 - 36:52

Thank you. That's helpful. And then secondly, recent court documents cited ongoing legal dispute between investors backing US partner Braeburn showed that there has been an offer made for Braeburn by an undisclosed party that was viewed unacceptable. So could you maybe use this opportunity to remind me where Camurus stands on its updated M&A agenda and key priorities?

Fredrik Tiberg
36:54 - 38:10

Yes. We remain focused on potential strategic assets, of course. And we are having ongoing activities on various different targets. of course. However, we have said that it needs to have a clear fit for our further development in the company. And so far, we haven't announced anything. So that's an important point. Also, we see some new opportunities in our pipeline. So we have and see the opportunity to invest further into both mid- and late-stage development potentially in our pipeline. So there will be some prioritizations to consider going forward. But definitely, it's part of our agenda. And as you know, we also now have on board, and part of her activities will, of course, be related to that area, as well as our strong BD group.

Matthias Haggblom
38:12 - 38:14

That's very helpful. Thanks so much.

Unknown 1
38:14 - 38:15

Thank you.

Operator
38:17 - 38:20

Next one from Dan Akschuti from Pareto Securities. Please go ahead.

Georg Tigalonov-Bjerke
38:22 - 38:25

Hi, everyone, and thank you for taking my questions.

Dan Akschuti
38:25 - 39:34

Just a follow up. It was briefly discussed already on Australia and also on the UK funding situation. If we look at the numbers from Q4 2023, it was performing better than Q1 this year. If you could just share a bit more what has been happening over the past years 2024, 2025, and this year. Then, on the UK funding situation, it sounds promising, but as you noted yourself earlier, it has been quite tricky for the money to actually be used in the clinics. If you have some more detailed knowledge on how it has been going since April, then one more general question. If there is time. And that is the stickiness of the current solutions that compete with Brixadi short-acting solutions. And what Braeburn is doing against that. And sorry, one more question. How many salespeople will actually be activated directly upon US approval for Oclaiz in the US? Thank you.

Richard Jameson
39:37 - 40:55

Should I start? Okay. So on Australia. Yes. The penetration is good in Australia. I think we have in the region of 30% of total market share now on Buvidal. And we maintain our leadership in the long-acting buprenorphine segment with above 80% share of that segment. So things are going well, and penetration is strong. And inevitably, you see growth rates slowing down a bit as you penetrate a market. I think there's still an opportunity in Australia. I still think we're seeing growth, and we will continue to see growth. Q1 is a bit of an anomaly because of the seasonal distribution holdings in Q4 that normalized in Q1. But then we expect that to come back in Q2. So that will go in the UK. Yes, the funding is a good question. Last year, they did announce the funding. It didn't come. And one of the problems was that it was only a year's funding. This time it's committed for three years. And I think it's very clear that the government intends that to make its way to invest in treatments of opioid dependence. So we have much more confidence, I think, that that money will come to the clinics, and it will take away some of the resistance, I think, of commissioners and clinics to start long-acting when they didn't have certainty about long-term funding. They now have that. So that should take away that issue.

Fredrik Tiberg
40:58 - 41:11

And regarding the US sales force you mentioned, I believe we have discussed approximately 20 people in the sales force for Oclaiz post-approval.

Dan Akschuti
41:13 - 41:20

And they are already trained, so they will be directly active, or will they be trained after approval?

Fredrik Tiberg
41:21 - 41:42

They will be active at the point of launch. The launch will then occur within a relatively short time frame from the approval. The active training will be implemented. Post approval.

Richard Ramanius
41:43 - 41:43

Okay.

Dan Akschuti
41:44 - 41:44

Okay. Thank you.

Operator
41:48 - 41:52

There are no more questions from the telco. So I hand the word back to you for closing comments.

Fredrik Tiberg
41:54 - 42:07

So thank you so much for listening in to this call, and looking forward to our update next time in July. It's been a pleasure today, and thank you for the questions.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…